Within two to four weeks we find potential targets/biomarker candidates or do a detailed target/biomarker assessment. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll contact you to discuss next steps.

Use our platform to find novel target/biomarker candidates or do detailed target/biomarker assessment yourselves. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll set up a demo to show you!

Please contact me to discuss:

Subscription to Euretos AI Platform
Euretos consulting service
Direct access to Euretos API

Do you have a question on gene-disease associations that are not covered on this page? Or would you like to know more about the Euretos AI Platform? Please fill in your contact details and we will reach out to you!

Kees Albers PhD joins Euretos as Chief Science Officer

Friday 02 November 2018

UTRECHT SCIENCE PARK - Euretos, a leading AI provider for in silico target and biomarker discovery, announced today that Kees Albers, Ph.D., has joined its leadership team as Chief Scientific Officer.

Prior to joining Euretos, Kees was assistant professor in the departments of Molecular Developmental Biology and Human Genetics at Radboud University and the Radboud University Medical Center. Here he led a combined ‘wet lab’ experimental and computational research group focusing on neuronal gene regulation and cellular function including therapeutic target discovery for neurodevelopmental disorders.

“I am very excited to join Euretos as its Chief Scientific Officer. There are tremendous opportunities for data integration in the life sciences. I am really looking forward to further expanding the Euretos AI platform with powerful machine learning algorithms to accelerate drug development.”

Before his positions at Radboud University, Kees was a research associate at the University of Cambridge and the Wellcome Trust Sanger Institute. As a member of the 1000 Genomes Project he developed a Bayesian approach to detect short insertions and deletions from one of the first large-scale population sequencing data sets and contributed to the development of the widely used vcf-file standard. He also analyzed sequencing data to identify the causative genes for a number of rare haematological disorders. Kees has a Masters degree in physics and obtained his PhD in 2008 from Radboud University.

“We are very happy that Kees will join Euretos and strengthen the leadership team with his unique experience in computational systems biology”, says Aram Krol, Co-Founder of Euretos. “He brings with him a wealth of experience in big data analytics, AI and computational biology in the research area of complex, x-omics disease mechanisms. Kees has the ideal background to further deepen and develop the computational models that power our data-driven systems biology approach to target and biomarker discovery and validation.”

About Euretos

Euretos, (www.euretos.com) founded in 2012 in the Netherlands, provides an AI platform mainly used by pre & early-clinical researchers for in-silico discovery & validation of targets, biomarkers and indications. The platform enables a systems biology approach where researchers discover how x-omics molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology. Cellular disease mechanisms are unravelled through deconvolution of differential expression profiles leveraging Euretos’ extensive cell type expression library to identify cellular interactions.

By integration of over 250 different public databases, the platform provides the largest single environment in which the latest multi omics data is interlinked to literature, experimental and clinical evidence. The data integrated in the platform include genetic, genomic and proteomic annotations, expression profiles, experimental and animal models, diseases, phenotypes, pathways, small molecules - covering metabolites, food ingredients, as well as therapeutic agents (antibodies and peptides).